| Name | Title | Contact Details |
|---|
Amorfix Life Sciences Ltd. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Progressive Radiology is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synbiotics Corporation offers a wide selection of canine reproductive services and products to breeders and veterinarians across the globe. Using advanced technology developed through years of research by leading scientists and veterinary specialists,
The mission of Crescendo Bioscience, Inc. is to enable more effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients. Crescendo Bioscience is currently focused on rheumatoid arthritis (RA), a debilitating, chronic disease affecting over 1.5 million people in the United States and more than 2 million in Europe. Although there is no known cure for RA, multiple therapies are available, with widely differing levels of effectiveness and significant potential toxicities. Choosing the optimal treatment from among these therapeutic alternatives is a tremendous challenge. At Crescendo Bioscience, we are committed to improving rheumatologists’ ability to understand the biology underlying RA and to better determine the status of a patient’s disease. Vectra® DA is the first and only multi-biomarker blood test validated to measure RA disease activity. Vectra DA integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score to help physicians make more informed treatment decisions. Crescendo Bioscience has also developed MyRA™, a free mobile app for people living with RA which was designed to empower patients to regularly track multiple aspects (e.g. medications, morning stiffness, joint pain, daily functionality, etc.) of their RA and easily share the information with their physician.
The healthcare industry is at a critical juncture, where every effort is being made to increase the effectiveness of care, while decreasing the financial burden on our system. With the introduction of BioTelemetry, we aim to lead in the advancement of mobile health monitoring by providing unmatched products and services to help healthcare professionals track and diagnose patients in a more efficient, accurate, and cost-effective manner. In April 2013, our predecessor company, CardioNet, Inc. (NASDAQ: BEAT), announced plans to adopt a holding company structure to more effectively facilitate our ongoing growth plans. With this change, our strategy is to achieve sustained long-term growth by solidifying our leadership position in remote cardiac monitoring, building a leading research services business, and identifying markets that would benefit from the application of our wireless platform and proprietary technology. We currently have four subsidiaries: CardioNet & Mednet- cardiac medical device & monitoring services, Braemar- cardiac manufacturing, Cardiocore- cardiac clinical research. Please visit our subsidiary pages for more information.